MEK inhibitors have been used in combination with other treatment modalities in RAS-mutant cancers, such as conventional chemotherapeutic agents [100], systemic immunotherapies [101,102] and Raf inhibitors [103,104] to sustain a prolonged clinical benefit. This evidence concerns the gene MAP2K7 and cancer.